Objective: The clinical importance of the metabolic syndrome (MeS) is confused by the existence of at least three different definitions proposed by prominent organizations, and by a lack of information about the prognostic value of diagnosing a person as having the syndrome by any of the definitions. Design and subjects: We used the US National Health and Nutrition Evaluation Survey (NHANES) to determine the prevalence in the United States of the variables used to define the MeS and cardiovascular disease (CVD), and to create a simulated population that matched the US population with respect to all the important characteristics, risk factors and treatments for CVD. We then used the Archimedes model to calculate the long-term CVD outcomes for each person in the simulated population. Results: The definitions implied an increased risk of CVD of 1.5-1.6. The definitions varied considerably in their ability to identify people at risk of myocardial infarctions (MIs); the proportion of people destined to have a future MI captured by the different definitions varied from 57 to 77%. The definitions also varied widely in how well they ruled out future MIs; failure to have MeS by a definition still left a chance of a future MI ranging from 23 to 42%. The definitions differed importantly in which people they identified as having MeS; 34% of those who met the ATP definition did not meet the WHO definition, 30% of those who met the WHO definition did not meet the ATP definition and 28% of those who met the IDF definition did not meet the ATP definition. Of the components of the definitions, the most important single factor for identifying a person at risk of future CVD was high glucose, with hypertension, obesity, high triglycerides and low HDL following in that order. High glucose, by itself, was as good as any definition of the MeS in predicting risk of future MI. Whichever definition was used, individuals who met the definition varied widely in their risk of CVD. Conclusions: For assessing a particular person's risk of future CVD and for making treatment decisions a diagnosis of MeS by any of the definitions added little if anything to assessing each person's risk factors.
The clinical importance of the metabolic syndrome (MeS) is confused by the existence of at least three definitions proposed by prominent organizations, and by a lack of information about the prognostic value of diagnosing a person as having the syndrome by any of the definitions. This analysis used data from the Third National Health and Nutrition Survey (NHANES III) and the Archimedes model to address the following questions: How much does a diagnosis of the MeS by any of the definitions increase the risk of current or future cardiovascular disease (CVD)? How important is the number of positive components of MeS? Does it matter which definition is used? How important are each of the individual components of MeS? Does a diagnosis of MeS add anything in simply examining a person's risk factors?
Methods NHANES III is a detailed survey and examination of approximately 40 000 persons in the United States. 1 It oversampled certain populations, but includes weights to enable reconstruction of a representative sample of the US population. We used it to estimate the prevalence of the variables relating to MeS and CVD, and to construct a simulated population that matched the US population, for analysis by the Archimedes model. The Archimedes model has been described elsewhere. [2] [3] [4] Briefly, it uses ordinary and differential equations and objectoriented programming to represent human physiology at a level of detail roughly comparable to that found in general medical textbooks or patient charts. 5 Of particular importance for this application is that the model has been validated against more than two dozen clinical trials that include people who meet the definitions of MeS. The Archimedes model can be linked to person-specific databases to calculate outcomes for that specific population. For this analysis, we used person-specific data from the NHANES III survey to create a population of simulated people who matched people in the US population with respect to more than three dozen variables, including epidemiological characteristics (for example, age, sex and race/ethnicity), biological variables (for example, BPs, cholesterols and insulin levels), behaviors (for example, smoking); past histories (for example, previous coronary artery disease), current diagnoses (for example, diabetes), and current treatments (for example, oral hypoglycemic drugs and aspirin). The method for creating the simulated individuals correctly reproduced the correlations of variables in the original data set. We then used the Archimedes model to calculate long-term CVD events for each individual and for subsets of the US population defined by each of the definitions of MeS.
Definitions of MeS
For this analysis, we used definitions of MeS proposed by three internationally prominent organizations. The Third Adult Treatment Panel (ATP III) defines a person to have MeS if they have three or more of the following: high glucose, obesity, low HDL, high triglycerides or hypertension. 6, 7 The
World Health Organization (WHO) requires high glucose and at least two of the following: obesity, dyslipidemia, hypertension or microalbuminuria. 8 The International
Diabetes Federation (IDF) requires obesity and at least two of the following: high glucose, low HDL, high triglycerides or hypertension.
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The organizations also differ in how they define the individual components. For example, obesity is defined by the ATP III as waist circumference 4102 cm for men or 488 cm for women; by the IDF as waist circumference X 94 cm for men or X80 cm for women; and by the WHO as waist-hip ratio 40.9 and/or BMI430 for men, waist-hip ratio 40.85 and/or BMI430 for women. High glucose is defined as FPG4110 mg per 100 ml by ATP III; as FPG4100 by IDF; and as FPG4100 or 2-h OGTT (OGT test) by the WHO. High glucose and low HDL have different cut points as well (the full definitions are as follows. ATP III: three or more of the following: FPGX110 mg per 100 ml, waist circumference 4102 cm for men or 488 cm for women, HDLo40 mg per 100 ml for men or o50 mg per 100 ml for women, triglycerides X150 mg per 100 ml or hypertension X130/85 mm Hg. WHO: diagnosed diabetes and/or FPG4100 mg per 100 ml and/or 2 h OGT440 mg per 100 ml and at least two of the following: waist-hip ratio 40.9 and/or BMI430 for men and waist-hip ratio 40.85 and/or BMI430 for women, triglycerides X150 mg per 100 ml or HDL o35 mg per 100 ml for men and triglycerides X150 mg per 100 ml or HDL o39 mg per 100 ml for women, SBP (systolic BP)X130 mm Hg or DBP (diastolic BP)X90, or urine albumin X20 mg min
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. IDF: BMI430 or waist circumference X94 cm for Europid men or X80 cm for Europid women, and at least two of the following: FPGX100 mg per 100 ml, triglycerides X150 mg per 100 ml, HDL o40 mg per 100 ml for men or o50 mg per 100 ml for women, or SBPX130 or DBPX85 mm Hg). Thus, there is general agreement that five main variables are importantFobesity, high triglycerides, low HDL, high BP and high glucoseFbut disagreement about the cut points that should be used to defined them, the appropriate way to weight and combine them, and the role of microalbuminuria.
How well do the different definitions identify people at risk of current or future CVD?
While the clinical interest in MeS centers predominantly on predicting future CVD, an indication of its ability to do that is how well it identifies people with prevalent CVD. Using the NHANES III population, the sensitivities and specificities of the three definitions for identifying adults (aged 40-74 years) with prevalent CVD (defined as a heart attack or congestive heart failure) are 55 and 65% for ATP III, 48 and 67% for WHO and 70 and 54% for IDF. The results imply a relative risk of 1.6 for the ATP criteria, and relative risks of about 1.5 for the WHO and IDF criteria, and are consistent with previous work. 10 Another way to view these results is to calculate how well each definition concentrates the risk of coronary artery disease. A good definition should capture a high proportion of people who have CVD in a small proportion of the overall population. To test this, we calculated the proportion of adults (aged 40-74 years) in the United States with CVD and the proportion of adults who met the various definitions of MeS. The results for the three definitions (marked WHO, ATP and IDF) are in Figure 1 . A perfect definition would have 100% of people with CVD captured in a small proportion of the overall population, marked 'perfect' on the figure. Flipping a coin would be in the center of the figure at the point (0.5, 0.5), marked 'coin' on the figure. The performances of the definitions were modest. The WHO was the most restrictive of the definitions, capturing about 45% of the CVD population in about 35% of the adult population. The IDF was the most inclusive, capturing about 70% of people with CVD in about 45% of the population.
To determine how well the definitions identify people who are destined to have future CVD, we used the Archimedes model to calculate the 30-year cumulative probability of a myocardial infarction (MI) in adults age X20 years as a whole ('average'), and compared that with the 30-year probabilities for adults X20 years who met the three definitions of MeS ( Figure 3 ) Compared with the average risk, each definition implied about a 70% increase in future risk (relative risk ¼ 1.7), which is similar to the performance of the three definitions in identifying people who already have CVD. Compared with people who do not have MeS, the three definitions implied relative risks for future MIs of 2.9, 2.6 and 3.9 for ATP III, WHO and IDF, respectively. Viewed as diagnostic tests for identifying people destined to have MIs in 30 years, the sensitivities and specificities of the three definitions were 61 and 68% for ATP III, 57 and 70% for WHO and 77 and 58% for IDF, respectively.
How important is the number of positive components of MeS? Does it matter which definition we use?
All three definitions perform about the same in identifying people with existing CVD and in predicting the risk of future MIs. In this sense, it does not make much difference which definition is used. However, the three definitions are quite different in that they identify different people.
For example, looking at people between 40 and 75 years in the United States, 34% of those who met the ATP III definition did not meet the WHO definition, 30% of those who met the WHO definition did not meet the ATP III definition and 28% of those who met the IDF definition did not meet the ATP III definition (Figure 2 ). Thus, while there is considerable overlap (22% of people aged 40-75 years meet all three definitions), there is also considerable nonoverlap. Furthermore, nuances in the definitions can have large effects.
The importance of these differences in the populations captured by different definitions, and the desirability of a particular definition, will depend on one's beliefs about the current level of care being delivered. If one believes people are generally not being treated for hypertension, dyslipidemia, and so forth, and if the role of identifying someone as having MeS is to motivate treatment, then a more inclusive 
Which components of MeS definitions are the most important?
One way to rank the importance of the MeS components is to calculate which one is associated with the highest rate of prevalent CVD. To determine this, we used data from the NHANES survey to calculate the proportion of people with each risk factor who have CVD, and compare that with the proportion of people with CVD who have the risk factor. We did this for each risk factor, one by one, for adults over the age of 20 years. The results are in Table 1 . For example, although obesity is the most prevalent risk factor in people with CVD (68% of people with CVD are obese), but only 6.9% of people who are obese have CVD. Thus, it is a highly prevalent risk factor, but is associated with only a 35% increase in risk (6.9/5.1 ¼ 1.35). On the other hand hyperglycemia, which is only about half as prevalent as obesity in people with CVD (36 vs 68%), is associated with a 9.7% rate of prevalent CVD (implying a 90% increase in risk compared with average). By this method, the ranking is high glucose, high BP, obesity, high triglycerides and low HDL.
It is important to understand that these results are not statements about the risk of CVD associated with a risk factor by itself; the high risk associated with any particular factor is in large part due to the other risk factors that come with it, that is, those which are correlated with it. Hyperglycemia is the most important neither because of its potency as a risk factor nor because of the relative importance of treating it, but because a lot of other risk factors are correlated with it. Another important note is that the centrality of glucose is such that it actually selects people with CVD better than any of MeS definitions. It captures 70% of the people with CVD in 35% of the population, and is the dot marked 'glucose' on Figure 1 . It is entirely possible that this is nearing the maximum we can expect from any definition of MeS.
Does a diagnosis of MeS add anything to simply examining a person's risk factors?
We approached this question in three parts. First, we examined the consistency with which MeS, by any of the definitions, sorts people into high vs low CVD risks. In fact, the definitions are inconsistent, and none of them are particularly effective in concentrating people in the at-risk population. This is seen in Figure 1 . It can also be illustrated by looking at specific cases. However, the second person's 30-year probability of a heart attack is almost five times higher (77%) than that of the first person (17%). These inconsistencies occur for two main reasons. First, the different risk factors have different effects. Simply counting them ignores that fact. Second, each risk factor is a continuous variable. Use of discrete thresholds for defining abnormality is artificial and discards crucial information about the magnitude of the risk factor. Second, we examined the proportion of CVD risk that is explained by the MeS variables. Here, it is pertinent that MeS does not consider such risk factors as age, sex, race/ethnicity, family history, behaviors such as smoking and exercise, past medical history such as MI, current symptoms such as angina, current treatments such as aspirin and so forth. For example, all else equal, simply an increase of 10 years implies a greater effect on risk of CVD than having MeS by any of the three definitions (26.1 vs about 20%). All else equal, smoking imparts a risk equivalent to having all five of the metabolic risk factors combined (34%).
A third perspective involves treatment. It is unclear how saying a person has MeS should change the treatments they would get based on their particular risk factors. If the purpose of diagnosing MeS is to target a subset of the population that should receive more intensive effort, then the current definitions are not very discriminatingFfrom a third to half of the world's adult population has been selected, depending on which definition is used (Figure 2) . Furthermore, selecting some people for increased attention implies that people who do not meet the criteria for MeS should receive less attention. To the extent that this occurs it could actually be harmful; the definitions miss from 23% (IDF) to 43% (WHO) of people destined to have future MIs.
Discussion
Metabolic syndrome has been a very provocative hypothesis that has stimulated important thinking and research. However, its clinical usefulness is blunted by the existence of competing definitions, by uncertainty about how a diagnosis of MeS affects a person's risk of future CVD, and by uncertainty about how diagnosing a person as having MeS improves on simply identifying and treating the person's individual risk factors.
Our analysis indicates that while the definitions do imply an increased risk of CVD of 1.5-1.6, they vary considerably in their clinical value. Concerning their ability to identify people at risk of MIs, the proportion of people destined to have a future MI captured by the different definitions varied from 57 to 77%. The definitions also varied widely in how well they ruled out future MIs; failure to have MeS by a definition still left a chance of a future MI ranging from 23 to 42%. The definitions differed importantly in which people they identified as having MeS; 34% of those who met the ATP definition did not meet the WHO definition, 30% of those who met the WHO definition did not meet the ATP definition and 28% of those who met the IDF definition did not meet the ATP definition. For identifying a person at risk of future CVD, an FPG4110 by itself did a better job of concentrating the risk of CVD than any of the definitions. For any of the definitions, individuals who met the definition varied widely in their risk of CVD.
A major barrier to establishing the clinical value of MeS is a lack of clarity about the primary reason for creating the syndrome in the first place. Is it to identify people who have an underlying biological abnormality that is driving MeS risk factors, like insulin resistance? Is it to identify people who are at especially high risk of future CVD or diabetes? Is it to identify people who are candidates for a treatment that goes beyond or is different from the treatments that are already specified for each of the syndrome's components? Is it to stimulate research? Or is the primary motivation something else? Until the purpose of MeS is defined it will be difficult to design a definition or choose between competing definitions.
Whatever the primary purpose, the simplicity of the current definitions, with their sharp cut points (for example, FPG4110) and their count-the-factors approach (for example, 'three of these five') severely limits their accuracy in identifying people for treatment. Dichotomizing variables that are inherently continuous and treating all factors as though they are equally important is inherently inaccurate. The logic for doing thisFto give clinicians a simple and easily remembered ruleFis understandable. But the cost in imprecision, both for stimulating research and for clinical care, is high. Furthermore, an approach that might start off searching for simplicity can easily turn complex as pieces are added and refined, and as competing rules are formulated.
For determining a person's risk of future CVD and for choosing treatments, a more accurate and clinically valuable approach is to take all the variables into account, preserve information about the magnitudes of the variables (instead of just considering them 'high' or 'low') and weight them in a physiologically realistic way. Given the ubiquity of electronic aids, this is easily accomplished with a calculator that includes all the important risk factors. The simple example of two patients offered above illustrates the value of a risk calculator that encompasses multiple CV risk factors in a continuous fashion compared with the simple risk assessment based on the MeS definitions. At the least, a calculator would end the quest for and competition between the various word-based definitions. In settings where access to a calculator is problematic, a truly simple count-the-factors approach could be used as an initial triage to determine which patients should be analyzed more accurately with a calculator. An obvious candidate for an ultra-simple screening tool is FPG4110. As seen in Figure 3 , for identifying prevalent CVD this factor by itself appears to perform at least as well as the three MeS definitions.
One of the greatest contributions of MeS is that it has integrated our thinking about the metabolic risk factors that affect CVD. Instead of diabetes being one of several 'independent' risk factors, the concept of MeS emphasizes that diabetes and other risk factors are connected through underlying mechanisms. While the immediate clinical usefulness of this is still uncertain, the implications for future research are huge. The concept of MeS holds out the possibility that there is a single pathological defect or pathway for which a targeted treatment might eventually be developed, thereby addressing at once several risk factors that currently require separate treatments.
Limitations
This work has several limitations. First, it is based on US data. While the general insights of this work are broadly applicable, the specific results may not apply in other countries or particular subsets of the US population. Second, because it is based on NHANES III, this analysis faces the same limitations faced by any other analysis that uses that database. These include the facts that not all variables are measured in all individuals (raising the possibility of selection biases), that for some people the values of biological variables are affected by treatments, and that some variables are not measured at all and force the use of proxies. Important examples are that NHANES III includes survey information, which is affected by patient recollection; that fasting insulin is only measured in about a third of the NHANES III population; that 2-h OGTT is only measured in people with diabetes, but not on insulin; and that albumin/creatinine ratio X30 had to be used as a proxy for urinary albumin excretion.
Third, the projections of future MIs are from a mathematical model. While the accuracy of the model has been validated against a large number of epidemiological studies 
